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ABSTRACT
Introduction While myeloma is an incurable malignancy, 
developments in disease management have led to 
increased life expectancy in recent years. Treatment 
typically involves stem-cell transplantation. Increased 
survival rates equate to more patients living with 
the burden of both the disease and its treatment for 
increasing number of years, rendering myeloma a 
long-term condition. Evidence exists to demonstrate 
the beneits of exercise for patients recovering from 
stem-cell transplantation, and prehabilitation—exercise 
before treatment—has been shown to be effective in 
other disease areas. To date there has been no research 
into prehabilitation in patients with myeloma awaiting 
transplantation treatment. Our objective is to determine 
whether it is feasible to conduct a randomised controlled 
trial into pretransplant exercise for patients with multiple 
myeloma who are awaiting autologous stem-cell 
transplantation.
Methods and analysis This mixed methods study 
identiies patients with diagnosis of multiple myeloma 
who have been assigned to the autologous transplantation 
list and invites them to participate in six weekly sessions 
of individualised, supervised exercise while awaiting 
transplantation. Quantitative data to determine feasibility 
targets include rates of recruitment, adherence and 
adverse events, and outcome measures including 6 min 
walking distance test and quality of life. Qualitative 
interviews are undertaken with a purposive sample of 
patients to capture their experiences of the study and the 
intervention.
Ethics and dissemination Ethics committee approval has 
been obtained. Dissemination will be through open-access 
publications and presentations and will seek to reach 
multiprofessional bases as well as patients and carer 
groups, addressing the widespread interest in this area of 
research.
Trial registration number NCT03135925; Pre-results.
INTRODUCTION
Myeloma is an incurable malignancy of anti-
body producing B lymphocytes and plasma 
cells. Equating to seven new cases per 100 000 
population in the UK, it represents 10% of all 
new haematological cancers.1 Disease symp-
toms include anaemia and hypercalcaemia 
causing fatigue and weakness, immunosup-
pression and lytic lesions of bone increasing 
pathological fracture risk.2
Due to developments in disease manage-
ment, life expectancy has increased signifi-
cantly in the last 10 years.3 The 5-year relative 
survival rate for England was 42.2% in 2011,4 
and is set to increase further due to earlier 
interventions in the disease process, more 
effective chemotherapies and increased use 
of autologous stem-cell transplantation.5
Strengths and limitations of this study
 ► The sample size for the qualitative aspect of this 
study is likely to be small—it is intended to inform 
future study design rather than provide deinitive 
understanding.
 ► For practical reasons and to encourage patient 
recruitment, time points for data collection are 
aligned with clinical interventions, rather than 
speciically for research purposes. They are 
therefore subject to variations, and not within the 
control of the study team.
 ► As a feasibility study, this will not provide evidence 
of the effectiveness of prehabilitation, but will inform 
future study design for evaluating effectiveness.
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Following diagnosis of multiple myeloma, the standard 
treatment for younger patients (generally, but not exclu-
sively, under the age of 70) with adequate fitness consists 
of an intensive pathway starting with induction treatment 
using a variety of regimens delivered as an outpatient or 
day case given to control disease until maximum response 
is achieved (usually reflected by a plateau in serum para-
protein).6–8 This response is then consolidated with 
autologous stem-cell transplantation, which permits the 
administration of high-dose myeloablative melphalan 
chemotherapy, a procedure typically requiring around 
3 weeks inpatient care, after which patients take several 
months to make a functional recovery.6–8 The procedure 
is non-curative and relapse/progression of myeloma 
occurs after an average of 2–3 years, which requires rein-
stitution of induction treatment, and, in many patients, 
consolidation with a second autologous transplant proce-
dure.9 10
Rationale for the study
Increased survival rates equate to more patients living 
with the burden of both the disease and its treatment 
for increasing number of years, rendering myeloma a 
long-term condition.11 The cumulative effects of the 
disease, compounded with the debilitating toxic nature 
of the treatment, impact significantly the quality of life 
of patients beyond the end of treatment, with late-effects 
symptoms including infection, fatigue, metabolic, neuro-
logical and cardiovascular disorders, as well as pain, phys-
ical fitness and psychological concerns.12
Only 20% of patients with myeloma meet national 
physical activity guidelines post-treatment,12and activity 
declines through treatment due to perceived barriers 
to exercise including pain, fear of injury and fatigue.13 
Although research evidence in physical activity has been 
demonstrated to be limited,14 evidence exists to demon-
strate the benefits of exercise for patients recovering 
from stem-cell transplantation.15 Prehabilitation after 
treatment in patients with myeloma has been shown to 
improve symptoms of physical performance, muscle 
strength, aerobic capacity, psychological outcomes, immu-
nological function and fatigue.16 Exercise training for 
myeloma survivors has been shown to be safe and feasible 
during treatment with high attendance and adherence17 
and has been implemented widely in clinical practice.
Studies demonstrate that pretransplant patients have 
reduced exercise capacity and increased comorbidities 
compared with a normal population, yet most rehabili-
tative interventions occur during and after treatment.15 
Thus, while exercise rehabilitation after treatment for 
myeloma can be effective, we must also consider rehabili-
tative interventions prior to the start of treatment: preha-
bilitation, defined as,
a process on the continuum of care that occurs 
between the time of cancer diagnosis and the be-
ginning of acute treatment … provides targeted in-
terventions that improve a patient's health to reduce 
the incidence and the severity of current and future 
impairments.18
Examples of prehabilitation exist in other clinical 
specialties: it has been used for some time in ortho-
paedic surgery to improve outcomes and postoperative 
recovery,19 and its economic benefits have been demon-
strated within colorectal surgery.20 A review of prehabil-
itation in patients with presurgical cancer demonstrated 
the effective use of aerobic interventions in the manage-
ment of patients undergoing thoracic surgery for lung 
cancer, identified the potential for its use in other 
oncology settings and called for further research to eval-
uate prehabilitation for wider groups of patients with 
cancer.19
Guidelines for the management of late and long-term 
effects of myeloma recommend that regular physical 
activity, including prehabilitation and rehabilitation, and 
aspiration to a general healthy lifestyle, are integral to 
patient care pathways.12
Autologous stem-cell transplantation has become the 
most common treatment in myeloma, with, for example, 
over 1400 performed in the UK annually, and procedures 
are performed in what is normally considered an elderly 
patient population, many with comorbidities and frailty. 
It is an intensive toxic procedure, with a recovery period 
of at least 6 months and strategies to improve recovery 
are warranted, including prehabilitation. A window of 
opportunity—usually a period of 4–6 months exists to 
offer prehabilitation between diagnosis or relapse and 
the commencement of the autologous stem-cell trans-
plantation process. Coleman et al21 studied 24 patients 
with multiple myeloma undergoing a home-based exer-
cise programme during chemotherapy and stem-cell 
transplantation and identified that no patient injured 
themselves and that the intervention had positive effects 
on lean body weight, fatigue and sleep disturbance. 
Despite this, no evidence currently exists regarding the 
use of prehabilitation exercise interventions in multiple 
myeloma.
This article describes the protocol for a study 
under way investigating the feasibility of research into 
the provision of an exercise intervention in patients 
with myeloma who are due to receive autologous stem-
cell transplantation.
AIMS AND OBJECTIVES
The aim of this study is to determine whether it is 
feasible to conduct a randomised controlled trial 
into pretransplant exercise for patients with multiple 
myeloma who are awaiting autologous stem-cell 
transplantation.
We will determine this through completion of the 
following objectives:
1. Assess the acceptability of the study to patients by 
measuring recruitment and retention to the study and 
through qualitative interview responses.
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2. Explore reasons for non-consent to study participa-
tion.
3. Establish whether a target cohort of patients exists.
4. Determine the most appropriate recruitment points 
postdiagnosis through steering group feedback, 
recruitment rate when compared with numbers 
invited to join the study and qualitative interview 
reports.
5. Assess the suitability of inclusion and exclusion crite-
ria by examining recruitment data.
6. Assess the acceptability of the intervention through 
qualitative interviews and retention rates during the 
study.
7. Determine duration of the intervention before trans-
plantation starts by monitoring point of recruitment 
to the study and time to transplant.
8. Explore the appropriateness of outcome measures/
completeness by qualitative interview responses, com-
pletion rates, time to complete.
METHODS AND ANALYSIS
Methodology
Mixed methods, combining qualitative and quantita-
tive data collection and analysis, are used to achieve the 
described aims and objectives.
Design
This is a prospective feasibility study (see figure 1 for 
study flow chart).
Setting
Assessments and exercise sessions take place in the physio-
therapy outpatient department in an acute hospital trust, 
which is a regional specialist centre for haematological 
services. Patient interviews take place in private rooms in 
the physiotherapy department or over the telephone for 
patient convenience.
Feasibility
The feasibility of the intervention is determined through 
the following targets:
Figure 1 Recruitment and intervention low chart. 6MWD, 6 min walking distance; DVD, digital versatile disc; PROMs, patient-
reported outcome measures. 
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 ► Recruitment: based on patient numbers at the study 
site, the recruitment target is 24 patients in a 12-month 
period (ie, two patients per month).
 ► Attendance: minimum average attendance at exercise 
sessions of 66% of the scheduled/invited sessions.
 ► Retention: 80% patient retention to 6-week follow-up 
assessment.
 ► Adverse events: adverse events are closely monitored 
and used to inform decisions to proceed.
Acceptability of the intervention to patients is also 
determined through the qualitative data collection and 
analysis, described in a later section.
Quantitative data collection and analysis
Data collection will take place between September 2016 
and February 2018.
Sampling
Consecutive sampling is used to recruit patients to this 
study who have a diagnosis of multiple myeloma and 
have been assigned to the autologous transplantation 
list. The recruiting centre transplants approximately 70 
patients with myeloma per year: sampling all patients 
over a 12-month period will indicate study recruitment 
feasibility. This feasibility study did not have a formal 
sample size calculation to determine a priori the number 
of participants to recruit; it aimed to recruit for a fixed 
period of time (12 months) at a single centre, and one 
of the outcomes was to estimate the recruitment rate per 
month.
Inclusion criteria
All patients with a diagnosis of multiple myeloma, 
assigned to the autologous transplantation waiting list for 
either a first or second transplant.22
Exclusion criteria
To allow safe completion of initial objective assessments, 
patients with a history of unstable angina or heart attack 
in the previous month are excluded.23 Medical stability is 
a prerequisite for transplantation, therefore no patients 
are excluded on this basis.
Recruitment
Patients are screened at clinic appointments by the 
bone marrow transplant team during their preparation 
for transplant. Patients meeting the inclusion criteria 
are provided with verbal and written information and 
invited to be involved in the study. Follow-up takes 
place after 48 hours via a phone call from a study phys-
iotherapist: any remaining questions are discussed, and 
if the patient agrees to take part then written consent 
is obtained and an initial assessment appointment is 
made.
Patients who choose not to join the study are invited 
to take part in a qualitative interview to explore their 
reasoning (figure 1). This is described in more detail 
under Qualitative data collection and analysis.
Intervention
Initial assessment
Patients attend an initial assessment with a study physio-
therapist who undertakes the following:
 ► explanation of the prehabilitation programme
 ► documentation of written consent
 ► subjective history including comorbidities and patient 
goals
 ► induction to the gym area equipment
 ► provision of booklet and digital versatile disc with 
physical activity advice
 ► baseline objective assessment (table 1)
 ► design of individualised gym programme in line with 
patient abilities and goals
 ► completion of an initial gym circuit with close 
supervision.
Weeks 2–5
Patients attend weekly 1-hour physiotherapist-led 
group gym sessions and complete their individualised 
programmes. Supervision is available as required and 
programmes are progressed in line with patient ability 
and performance.
Week 6
Completion of final gym circuit and repeat of objective 
assessments (table 1).
Table 1 Study data collection
Recruitment
Initial 
assessment Weeks 2–5 Week 6
Transplant 
admission
Transplant 
discharge
Screening data ✓
Demographic data ✓
6 min walking 
distance test
✓ ✓ ✓ ✓
PROMs ✓ ✓ ✓ ✓
Activity data ✓ ✓ ✓ ✓ ✓
Adverse events ✓ ✓ ✓
PROMs, patient-reported outcome measures.
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Follow-up
Patients are followed up on admission for transplant, and 
again on transplant discharge, for further repeat of objec-
tive assessments (table 1).
Outcome measures
The following data are captured for study participants.
Screening data
Through initial screening and recruitment, data are 
collected on:
 ► number of patients meeting inclusion criteria
 ► patients accepting initial study information
 ► patients agreeing to attend for initial assessment
 ► reasons for non-participation.
Demographic data
The following demographic data are captured during the 
initial assessment:
 ► gender
 ► length of diagnosis
 ► baseline physical activity levels
 ► transplant history
 ► pretransplant therapies received
 ► time to transplantation from decision to transplant
 ► other relevant information.
Functional measure
Patients undertake a 6 min walking distance (6MWD) test 
before and after the exercise intervention. The 6MWD test 
is a useful field test of functional capacity, is safe to admin-
ister and although it has less correlation with peak oxygen 
capacity than the shuttle walk test, it is better tolerated by 
patients and is more reflective of activities of daily living 
as it is a submaximal exercise test.23 The  6MWD  test has 
been found to be a valid and reliable test in patients with 
cancer.24
Patient reported outcome measures
As this is a feasibility study, it is useful to determine the 
feasibility and acceptability of outcomes to be used. For 
this reason, two different sets of patient reported outcome 
measures (PROMs) are issued to alternate patients taking 
part in the study (table 2). The data collected in the 
outcome measures and in the qualitative interviews will 
determine their value in any future studies.
Activity data
The following activity data are collected for each 
participant:
 ► the number of gym attendances
 ► follow-up compliance
 ► withdrawals from the study and at which stage of the 
study these occur
 ► reasons for withdrawal or non-attendance.
Data collection
Table 1 shows the full data collection schedule for the 
study.
Data analysis
Flow of participants through the study is captured, and 
the baseline clinical and demographic characteristics 
of consented participants assessed with appropriate 
summary statistics.
The data analysis for the feasibility objectives uses 
descriptive statistics and focuses on CI estimation.
1. The feasibility of recruitment to main trial is assessed 
with the consent rate (defined as the ratio of number 
of consented participants/number of eligible partici-
pants) and its associated 95% CI, and the recruitment 
rate per month and its associated 95% CI. The target 
recruitment rate is a minimum of two participants per 
month.
2. Reporting of the number and characteristics of eligi-
ble patients approached for the study and reasons for 
refused consent
3. Reporting of study participant retention rates at 6-week 
follow-up (eg, participants with a valid   6MWD  out-
come— the probable primary outcome for the main 
trial) and its associated 95% CI. The target is a min-
imum of 80% retention to 6-week follow-up assess-
ment.
4. Reporting of the number (and rate) of serious ad-
verse events/incidents (and its associated 95% CI) 
experienced by the participants in the pretransplanta-
tion period. A serious adverse event (SAE) is defined 
as any adverse event or adverse reaction that results 
in death, is life-threatening, requires hospitalisation 
or prolongation of existing hospitalisation, results in 
persistent or significant disability or incapacity, or is a 
congenital anomaly or birth defect.
5. Reporting of the decision on primary endpoint for 
any main trial (current estimate suggests 80% power, 
two-sided, with n=610 to detect 5% (18 metre) differ-
ence in 6MWD  test with 10% dropout at 12 metre).
Table 2 Patient reported outcome measures
Group Category Measure
Physical activity/
itness
Group 1 International Physical 
Activity Questionnaire25
Group 2 Godin Leisure Time26
Mental well-being Groups 1 
and 2
Warwick and Edinburgh 
Mental Well-being 
Scale27
Quality of Life Group 1 Functional Assessment 
of Cancer Therapy 
- Multiple Myeloma 
(FACT-MM)28
Group 2 European Organisation 
of Cancer Treatment 
Quality of Life 
Questionnaire (EORTC 
QLQ)29
Self-eficacy for 
exercise
Groups 1 
and 2
Self-Eficacy for 
Exercise Scale30
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Qualitative data collection and analysis
Sampling and data collection
The aim of the qualitative data collection and analysis is 
to explore in greater detail patients’ perceptions of the 
study including its acceptability, as well as barriers and 
facilitators to participation.
Patients who decline to take part in the exercise trial are 
asked if they would undertake a short telephone interview 
to ascertain their reasons for not taking part in the study. 
Participants who have already consented to take part in 
the trial and are undertaking the exercise programme are 
approached by a member of the clinical team and asked if 
they would be interested in taking part in a series of face-
to-face or telephone interviews (figure 1).
The interview topic guide is informed by evidence 
regarding acceptability and barriers and facilitators to 
participation from previous studies in prehabilitation and 
studies of exercise in patients with multiple myeloma.17 21 It 
is also tailored to match developments and areas of interest 
that emerged from the quantitative data collection as the 
study progresses. The topic guide is flexible to enable 
exploration of individual experiences, for example, those 
who had fully completed the intervention compared with 
those who may have had only limited participation.
Topic areas include reasons for non-participation, partici-
pants' characteristics and descriptive information regarding 
the nature of their disease management to date; the patient 
experience of the intervention, with reference to aspects 
that may impact the design of future study, for example, 
recruitment, ease or difficulty of attendance, timing and 
nature of data collection, suitability of outcome measures; 
barriers and enablers to participation in the study.
Qualitative analysis
The framework approach is used to analyse the qualita-
tive data.25 This method is appropriate for identifying, 
analysing, and reporting themes and patterns within data. 
It is a flexible and useful research tool, which can poten-
tially provide a rich and detailed, yet simple account of data. 
Early on in the analysis the transcripts are repeatedly read 
to develop an understanding of the breadth and depth of 
the data. During this process, data are labelled and coded 
in an iterative process whereby patterns and sequences of 
content over time are identified within and across all the 
participants. Emergent themes are further developed and 
refined by analysing similarities and divergences between 
and within the participants, to form a coherent pattern.26
ETHICS AND DISSEMINATION
Ethical consideration
Ethical issues relating to informed consent and confi-
dentiality are addressed throughout. It is acknowledged 
that patients approached and participating in this study 
may be physically debilitated and experiencing anxiety, 
having received a new cancer diagnosis and awaiting a 
challenging programme of treatment. Due care and dili-
gence are taken when consenting potential subjects and 
the option to withdraw from the study at any point is reit-
erated. In particular, the nature of qualitative interviews, 
focusing on personal experiences of illness and treat-
ment, may result in some distress to some participants. 
The researchers have relevant experience in working with 
patients with life-threatening illness and are skilled at 
talking to them, as well as being able to recognise patient 
distress.
Dissemination
This study has involvement from, and relevance to, the 
professions of physiotherapy, medicine and nursing. 
Dissemination will incorporate each of these professions 
and reach into the wider healthcare community. We will 
seek to share the findings of the study through local, 
national and international channels.
Patient involvement in the project has been through 
representation in study design and on the project steering 
group from the North Trent Cancer Research Network 
Consumer Research Panel. We will liaise with this group 
to invite ideas regarding dissemination to study partici-
pants, patients and carers.
Where the findings of the study have implications for 
the provision of new or existing services to patients with 
myeloma, we will ensure dissemination to relevant key 
opinion leaders and stakeholders to support decision 
making.
DISCUSSION
It is anticipated that this study will demonstrate the feasi-
bility of conducting research into prehabilitation physical 
activity programmes. Factors likely to affect feasibility 
may include patient perception of the role of physical 
activity; patient time commitments; patient wellness to 
take part and patient enjoyment of exercise.
If feasibility is confirmed then we will seek to establish 
a larger scale study to test the efficacy of the interven-
tion. The findings from this study will be used to support 
power and sample size calculations and to establish suit-
able outcome measures for future studies.
If the feasibility criteria are not satisfied then there 
will be lessons to learn regarding the potential for future 
studies in the field, or modifications to the intervention 
or study design if further study is indicated. Since preha-
bilitation is an area of growing interest in other clinical 
areas, including other cancer and non-cancer patholo-
gies, then it is anticipated that the findings of this study 
will also be of interest to practitioners considering preha-
bilitation outside of myeloma.
Establishing the feasibility of research in this field is 
important to explore the case for prehabilitation. The 
effects of bone marrow transplantation can have a high 
cost to the individual and to health services. There is 
clearly of value in exploring treatment options that may 
lessen the effects of treatment, particularly those with rela-
tively low associated costs such as exercise prehabilitation.
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